Maintenance pharmacotherapy of mild and moderate COPD: What is the evidence?

Respiratory Medicine

Volumn 105, Issue 9, 2011, Pages 1268-1274

  Ferguson, Gary T ^a  

^a Pulmonary Research Institute of Southeast Michigan   (United States)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Inhaled corticosteroids; Mild; Moderate; Pharmacotherapy

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICAL TOLERANCE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; SMOKING CESSATION;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 79960457533     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2011.02.005     Document Type: Review

References (45)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. Available from: http://www.goldcopd.org; [accessed 07.01.10].
2. M.B. Stephens, and K.S. Yew Diagnosis of chronic obstructive pulmonary disease Am Fam Physician 78 2008 87 92
3. D. Ofir, P. Laveneziana, K.A. Webb, Y.-M. Lam, and D.E. O'Donnell Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease Am J Respir Crit Care Med 177 2008 622 629 (Pubitemid 351442169)
4. R.G. Barr, D.A. Bluemke, F.S. Ahmed, J.J. Carr, P.L. Enright, and E.A. Hoffman Percent emphysema, airflow obstruction, and impaired left ventricular filling N Engl J Med 362 2010 217 227
5. F. Pedersen, I. Raymond, J. Mehlsen, D. Atar, and P.R. Hildebrandt Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly Am J Med 118 2005 25 31 (Pubitemid 40082455)
6. World Health Organization. Chronic obstructive pulmonary disease. Fact sheet No. 315. Available from: http://www.who.int/mediacentre/factsheets/fs315/ en; [accessed 07.09.09].
7. World Health Organization. World Health Statistics 2008. Available from: http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf; [accessed 08.09.09].
8. National Institutes of Health. Morbidity & Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases, http://www.nhlbi.nih.gov/ resources/docs/2009-ChartBook.pdf; 2010 [accessed 22.04.10].
9. D.M. Mannino, D.M. Homa, L.J. Akinbami, E.S. Ford, and S.C. Redd Chronic obstructive pulmonary disease surveillance-United States, 1971-2000 MMWR Surveill Summ 51 2002 1 16
10. D.G. Tinkelman, D. Price, R.J. Nordyke, and R.J. Halbert COPD screening efforts in primary care: what is the yield? Prim Care Respir J 16 2007 41 48 (Pubitemid 46364355)
11. G. van den Boom, M.P. Rutten-van Molken, P.R. Tirimanna, C.P. van Schayck, H. Folgering, and C. van Weel Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme Eur Respir J 11 1998 67 72 (Pubitemid 28081797)
12. D.G. Tinkelman, D.B. Price, R.J. Nordyke, and R.J. Halbert Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over J Asthma 43 2006 75 80
13. B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, and A.S. Buist Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946 (Pubitemid 38807371)
14. D.E. O'Donnell, P. Hernandez, A. Kaplan, S. Aaron, J. Bourbeau, and D. Marciniuk Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care Can Respir J 15 Suppl. A 2008 1A 8A (Pubitemid 351566057)
15. M. Bednarek, D. Gorecka, J. Wielgomas, M. Czajkowska-Malinowska, J. Regula, and G. Mieszko-Filipczyk Smokers with airway obstruction are more likely to quit smoking Thorax 61 2006 869 873 (Pubitemid 44570307)
16. C. Fletcher, and R. Peto The natural history of chronic airflow obstruction Br Med J 1 1977 1645 1648 (Pubitemid 8124466)
17. A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T.J. Wilt, and S. Weinberger Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians Ann Intern Med 147 2007 633 638 (Pubitemid 351664484)
18. C. Jenkins, P. Jones, P. Calverley, B. Celli, J. Anderson, and G. Ferguson Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Respir Res 10 2009 59
19. M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra, and D.P. Tashkin Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet 374 2009 1171 1178
20. 1. The Lung Health Study JAMA 272 1994 1497 1505
21. J.C. Hogg Pathophysiology of airflow limitation in chronic obstructive pulmonary disease Lancet 364 2004 709 721 (Pubitemid 39140629)
22. J.C. Hogg, F. Chu, S. Utokaparch, R. Woods, W.M. Elliott, and L. Buzatu The nature of small-airway obstruction in chronic obstructive pulmonary disease N Engl J Med 350 2004 2645 2653 (Pubitemid 38787999)
23. P.J. Barnes Chronic obstructive pulmonary disease N Engl J Med 343 2000 269 280 (Pubitemid 30490396)
24. E. Repine John, A. Bast, and I.D.A. Lankhorst The oxidative stress study group. Oxidative stress in chronic obstructive pulmonary disease Am J Respir Crit Care Med 156 1997 341 357 (Pubitemid 27351964)
25. P.O. Bridevaux, M.W. Gerbase, N.M. Probst-Hensch, C. Schindler, J.M. Gaspoz, and T. Rochat Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD Thorax 63 2008 768 774
26. J.F. O'Reilly, A.E. Williams, K. Holt, and L. Rice Defining COPD exacerbations: impact on estimation of incidence and burden in primary care Prim Care Respir J 15 2006 346 353 (Pubitemid 44810150)
27. T.A. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, and J.A. Wedzicha Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 1418 1422
28. M. Decramer, S. Rennard, T. Troosters, D.W. Mapel, N. Giardino, and D. Mannino COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention COPD 5 2008 235 256
29. D. Zaas, R. Wise, and C. Wiener Airway obstruction is common but Unsuspected in patients admitted to a general Medicine service Chest 125 2004 106 111 (Pubitemid 38114571)
30. B.P. Yawn, and P.C. Wollan Knowledge and attitudes of family physicians coming to COPD continuing medical education Int J Chron Obstruct Pulmon Dis 3 2008 June 311 318
31. COMBIVENT Inhalation Aerosol Study Group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial Chest 105 1994 1411 1419
32. N.A. Hanania, P. Darken, D. Horstman, C. Reisner, B. Lee, and S. Davis The efficacy and safety of fluticasone propionate (250 μg)/Salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD Chest 124 2003 834 843 (Pubitemid 37123298)
33. R.A. Pauwels, C.-G. Lofdahl, L.A. Laitinen, J.P. Schouten, D.S. Postma, and N.B. Pride Long-Term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking N Engl J Med 340 1999 1948 1953 (Pubitemid 29288270)
34. The Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 2000 1902 1909
35. P.S. Burge, P.M.A. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, and T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 2000 1297 1303 (Pubitemid 30245717)
36. P.W. Jones, L.R. Willits, P.S. Burge, and P.M.A. Calverley Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations Eur Respir J 21 2003 68 73 (Pubitemid 36150303)
37. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789 (Pubitemid 46294610)
38. B.R. Celli, N.E. Thomas, J.A. Anderson, G.T. Ferguson, C.R. Jenkins, and P.W. Jones Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
39. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
40. G. Johansson, A. Lindberg, K. Romberg, L. Nordstrom, F. Gerken, and A. Roquet Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD Prim Care Respir J 17 2008 169 175
41. US Food and Drug Administration. ADVAIR DISKUS(R) label. US Food and Drug Administration. April 30, 2008. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/021077s029lbl.pdf; [accessed 06.05.10].
42. US Food and Drug Administration. SPIRIVA HandiHaler label. US Food and Drug Administration. December 2009. Available from: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/021395s029lbl.pdf; [accessed 22.07.10].
43. A. Anzueto, G.T. Ferguson, G. Feldman, K. Chinsky, A. Seibert, and A. Emmett Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes COPD 6 2009 320 329
44. G.T. Ferguson, A. Anzueto, R. Fei, A. Emmett, K. Knobil, and C. Kalberg Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations Respir Med 102 2008 1099 1108
45. US Food and Drug Administration SYMBICORT(R) label. US Food and Drug Administration. February 27, 2009. Available from: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/021929s012lbl.pdf; [accessed 06.05.10].